bioMérieux announced that it has entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”).
SpinChip’s small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments. bioMérieux has held a minority stake in SpinChip since March 2024.
SpinChip is initially developing lab-quality tests to address indications that are common in acute care settings, and in particular Myocardial Infarction (MI) which is a leading cause of morbidity and mortality worldwide.
SpinChip will first focus on well-established and utilized cardiac markers like high-sensitive troponin I (hs-TnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and D-Dimer and will expand testing to other clinical areas important in acute care settings. The performance of the first assay in the menu, hs-TnI, has been validated in a retrospective clinical study with the APACE cohort and is currently being assessed in a multicenter European clinical trial. SpinChip expects to lodge an application for CE marking under the IVDR before the end of 2025.
